PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy

Sanchita Mallick, Jaiprakash Agarwal, Sadhana Kannan, Sagar Pawar, Shubhada Kane, Tanuja Teni

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

At our laboratory, we recently observed cell cycle and apoptosis-related proteins Myeloid Cell Leukemia-1 (Mcl-1) and Proliferating Cell Nuclear Antigen (PCNA) to be altered in oral tumours/cell lines. The present study aimed to evaluate the above proteins for predicting response and outcome in oral cancer patients treated with definitive radiotherapy. Pre-treatment oral cancer biopsy samples from 39 patients were examined for Mcl-1 and PCNA proteins using immunohistochemistry and correlated with clinico-pathological variables using disease-free survival (DFS) as the primary endpoint. We observed high expression of Mcl-1 in older versus younger patients (ρ = 0.013) and in tobacco chewers ± alcohol versus smokers ± alcohol (ρ = 0.037); and PCNA in node-positive versus node-negative tumours (ρ = 0.037). On univariate analysis, high PCNA (ρ = 0.007), Mcl-1 (ρ = 0.050), node positivity (ρ = 0.040) and co-expression of PCNA and Mcl-1 (ρ = 0.008), had a significant impact on DFS. On multivariate analysis, low PCNA/Mcl-1 (ρ = 0.006) co-expressing tumours were associated with improved DFS. Thus our study suggests that in patients undergoing primary radiotherapy, PCNA could be of potential predictive value to identify patients with risk of nodal metastases and in combination with Mcl-1 may have potential prognostic value to differentiate patients with poor DFS. These markers may be used for future trial patients requiring radiotherapy for their treatment.

Original languageEnglish (US)
Pages (from-to)688-693
Number of pages6
JournalOral Oncology
Volume46
Issue number9
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Myeloid Leukemia
Mouth Neoplasms
Proliferating Cell Nuclear Antigen
Myeloid Cells
Disease-Free Survival
Radiotherapy
Proteins
Alcohols
Nuclear Proteins
Tumor Cell Line
Tobacco
Neoplasms
Cell Cycle
Multivariate Analysis
Immunohistochemistry
Apoptosis
Neoplasm Metastasis
Biopsy
Therapeutics

Keywords

  • DFS
  • Immunohistochemistry
  • Mcl-1
  • Nodal metastases
  • Oral cancer
  • PCNA
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy. / Mallick, Sanchita; Agarwal, Jaiprakash; Kannan, Sadhana; Pawar, Sagar; Kane, Shubhada; Teni, Tanuja.

In: Oral Oncology, Vol. 46, No. 9, 01.09.2010, p. 688-693.

Research output: Contribution to journalArticle

Mallick, Sanchita ; Agarwal, Jaiprakash ; Kannan, Sadhana ; Pawar, Sagar ; Kane, Shubhada ; Teni, Tanuja. / PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy. In: Oral Oncology. 2010 ; Vol. 46, No. 9. pp. 688-693.
@article{e2e63c648f7a49bcbad776e56e845bd1,
title = "PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy",
abstract = "At our laboratory, we recently observed cell cycle and apoptosis-related proteins Myeloid Cell Leukemia-1 (Mcl-1) and Proliferating Cell Nuclear Antigen (PCNA) to be altered in oral tumours/cell lines. The present study aimed to evaluate the above proteins for predicting response and outcome in oral cancer patients treated with definitive radiotherapy. Pre-treatment oral cancer biopsy samples from 39 patients were examined for Mcl-1 and PCNA proteins using immunohistochemistry and correlated with clinico-pathological variables using disease-free survival (DFS) as the primary endpoint. We observed high expression of Mcl-1 in older versus younger patients (ρ = 0.013) and in tobacco chewers ± alcohol versus smokers ± alcohol (ρ = 0.037); and PCNA in node-positive versus node-negative tumours (ρ = 0.037). On univariate analysis, high PCNA (ρ = 0.007), Mcl-1 (ρ = 0.050), node positivity (ρ = 0.040) and co-expression of PCNA and Mcl-1 (ρ = 0.008), had a significant impact on DFS. On multivariate analysis, low PCNA/Mcl-1 (ρ = 0.006) co-expressing tumours were associated with improved DFS. Thus our study suggests that in patients undergoing primary radiotherapy, PCNA could be of potential predictive value to identify patients with risk of nodal metastases and in combination with Mcl-1 may have potential prognostic value to differentiate patients with poor DFS. These markers may be used for future trial patients requiring radiotherapy for their treatment.",
keywords = "DFS, Immunohistochemistry, Mcl-1, Nodal metastases, Oral cancer, PCNA, Prognostic factors, Radiotherapy",
author = "Sanchita Mallick and Jaiprakash Agarwal and Sadhana Kannan and Sagar Pawar and Shubhada Kane and Tanuja Teni",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.oraloncology.2010.04.003",
language = "English (US)",
volume = "46",
pages = "688--693",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy

AU - Mallick, Sanchita

AU - Agarwal, Jaiprakash

AU - Kannan, Sadhana

AU - Pawar, Sagar

AU - Kane, Shubhada

AU - Teni, Tanuja

PY - 2010/9/1

Y1 - 2010/9/1

N2 - At our laboratory, we recently observed cell cycle and apoptosis-related proteins Myeloid Cell Leukemia-1 (Mcl-1) and Proliferating Cell Nuclear Antigen (PCNA) to be altered in oral tumours/cell lines. The present study aimed to evaluate the above proteins for predicting response and outcome in oral cancer patients treated with definitive radiotherapy. Pre-treatment oral cancer biopsy samples from 39 patients were examined for Mcl-1 and PCNA proteins using immunohistochemistry and correlated with clinico-pathological variables using disease-free survival (DFS) as the primary endpoint. We observed high expression of Mcl-1 in older versus younger patients (ρ = 0.013) and in tobacco chewers ± alcohol versus smokers ± alcohol (ρ = 0.037); and PCNA in node-positive versus node-negative tumours (ρ = 0.037). On univariate analysis, high PCNA (ρ = 0.007), Mcl-1 (ρ = 0.050), node positivity (ρ = 0.040) and co-expression of PCNA and Mcl-1 (ρ = 0.008), had a significant impact on DFS. On multivariate analysis, low PCNA/Mcl-1 (ρ = 0.006) co-expressing tumours were associated with improved DFS. Thus our study suggests that in patients undergoing primary radiotherapy, PCNA could be of potential predictive value to identify patients with risk of nodal metastases and in combination with Mcl-1 may have potential prognostic value to differentiate patients with poor DFS. These markers may be used for future trial patients requiring radiotherapy for their treatment.

AB - At our laboratory, we recently observed cell cycle and apoptosis-related proteins Myeloid Cell Leukemia-1 (Mcl-1) and Proliferating Cell Nuclear Antigen (PCNA) to be altered in oral tumours/cell lines. The present study aimed to evaluate the above proteins for predicting response and outcome in oral cancer patients treated with definitive radiotherapy. Pre-treatment oral cancer biopsy samples from 39 patients were examined for Mcl-1 and PCNA proteins using immunohistochemistry and correlated with clinico-pathological variables using disease-free survival (DFS) as the primary endpoint. We observed high expression of Mcl-1 in older versus younger patients (ρ = 0.013) and in tobacco chewers ± alcohol versus smokers ± alcohol (ρ = 0.037); and PCNA in node-positive versus node-negative tumours (ρ = 0.037). On univariate analysis, high PCNA (ρ = 0.007), Mcl-1 (ρ = 0.050), node positivity (ρ = 0.040) and co-expression of PCNA and Mcl-1 (ρ = 0.008), had a significant impact on DFS. On multivariate analysis, low PCNA/Mcl-1 (ρ = 0.006) co-expressing tumours were associated with improved DFS. Thus our study suggests that in patients undergoing primary radiotherapy, PCNA could be of potential predictive value to identify patients with risk of nodal metastases and in combination with Mcl-1 may have potential prognostic value to differentiate patients with poor DFS. These markers may be used for future trial patients requiring radiotherapy for their treatment.

KW - DFS

KW - Immunohistochemistry

KW - Mcl-1

KW - Nodal metastases

KW - Oral cancer

KW - PCNA

KW - Prognostic factors

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=77956394297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956394297&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2010.04.003

DO - 10.1016/j.oraloncology.2010.04.003

M3 - Article

C2 - 20729132

AN - SCOPUS:77956394297

VL - 46

SP - 688

EP - 693

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 9

ER -